Pfizer (PFE)SVP & Controller sold ~$65K

~$65K

Approx. value · 2,500 sh @ $25.93

12K

Holds after · shares reported

Traded

Mar 4, 2025

Filed

Mar 6, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 15, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
2. Jan 24, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
3. Jan 31, 2025FDAFDA drug approval: Paxlovid (Copackaged)
4. Feb 12, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
5. Feb 13, 2025InsiderDirector purchased ~$499K of PFE shares in the open market
6. Feb 13, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
7. Feb 21, 2025FDAFDA drug approval: Xeljanz
8. Feb 21, 2025FDAFDA drug approval: Xeljanz XR
9. Feb 24, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
10. Feb 25, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
11. Feb 26, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
12. Mar 3, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
13. Mar 4, 2025 · this disclosureInsiderOfficer sold ~$65K of PFE shares in the open market

What came next

1. Mar 10, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
2. Mar 12, 2025FDAFDA drug approval: Mektovi
3. Mar 12, 2025FDAFDA drug approval: Braftovi
4. Mar 31, 2025Congress · 1 personMembers of Congress: 2 sales
5. Apr 8, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
6. Apr 11, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
7. Apr 21, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
8. Apr 23, 2025FDAFDA drug approval: Ibrance
9. Apr 23, 2025FDAFDA drug approval: Ibrance
10. Apr 29, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
11. May 15, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
12. May 28, 2025FDARecall: DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, For Intravenous Use Only, Made in Italy,…
13. May 30, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
14. Jun 3, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
15. Jun 12, 2025FDAFDA drug approval: Talzenna
16. Jun 12, 2025FDAFDA drug approval: Talzenna

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Pfizer

For Pfizer, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

Other recent filings by Jennifer B. Damico, SVP & Controller

• SEC Form 4 at Pfizer (PFE)Aug 6, 2026
• SEC Form 4 at Pfizer (PFE)Jun 10, 2026

The full history of Jennifer B. Damico, SVP & Controller is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Pfizer

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its PFE page.